Highlights
- Wockhardt reported positive profit before tax in FY26 after losses in the previous year.
- Q4 FY26 revenue and EBITDA increased significantly compared to the same quarter last year.
- Biotech and emerging markets businesses contributed strongly to overall growth during the year.
Wockhardt Limited (NSE:WOCKPHARMA) reported revenue of ₹965 Cr in Q4 FY26, compared to ₹743 Cr in Q4 FY25, reflecting a 30% increase
EBITDA for the quarter stood at ₹196 Cr, rising from ₹79 Cr in the previous year, showing strong improvement in operating performance
Profit before tax (PBT) came at ₹189 Cr compared to a loss of ₹22 Cr in Q4 FY25, while profit after tax (PAT) stood at ₹164 Cr versus a loss of ₹45 Cr last year
FY26 Annual Financial Performance
For the full year ended March 31, 2026, the company reported revenue of ₹3,373 Cr, up 11% from ₹3,033 Cr in FY25
EBITDA increased to ₹630 Cr from ₹418 Cr, reflecting a 51% growth
The company reported a profit before tax of ₹238 Cr compared to a loss of ₹16 Cr in the previous year
Profit after tax stood at ₹199 Cr compared to a loss of ₹57 Cr in FY25
Exceptional Items and One-Time Adjustments
The financial results included exceptional items such as restructuring costs and regulatory-related charges
These included the impact of US entity liquidation, settlement with a bankruptcy trustee, and compliance-related expenses
The company also recorded a credit from a settlement agreement with Dr. Reddy’s Laboratories amounting to ₹35.35 Cr
Biotech Segment Performance
Biotech operations contributed ₹252 Cr in Q4 FY26, showing a 126% increase compared to the previous year
For the full year, biotech revenue stood at ₹697 Cr, reflecting 27% growth
Growth was supported by emerging markets and increased demand in key regions such as Thailand, Egypt, and Latin America
Regional Business Performance
India branded business reported ₹112 Cr revenue in Q4 FY26, growing 18% year-on-year
The UK business recorded ₹349 Cr revenue in Q4 FY26, showing a 20% increase
Emerging markets revenue stood at ₹320 Cr, rising 124% compared to last year, supported by biotech insulin products
Ireland operations reported ₹52 Cr revenue, reflecting a 12% increase
Product Development and Pipeline Updates
During the period, the company completed multiple product filings, approvals, and launches across international markets
Five novel antibiotics completed Phase 3 clinical trials, including Emrok, Miqnaf, and Zaynich
Zaynich received accelerated assessment from the European regulator, while regulatory reviews are ongoing in the US and Europe
Miqnaf has been approved and launched in India, with expanded market access following regulatory changes
Operational Developments
The company continued to focus on research and development with total R&D spend at ₹120 Cr for FY26
Patent activity remained steady with one new patent filed and one granted during the quarter
Key Risks
- Regulatory approvals may face delays impacting product launches
- High dependence on international markets exposes revenue to global demand changes
- Exceptional items and restructuring costs may affect profitability consistency
- Currency fluctuations can impact earnings from overseas operations
Share Performance
Wockhardt Limited (NSE:WOCKPHARMA) is currently experiencing a powerful breakout, surging +8.76% to reach 1,549.80 as of May 6, 2026. This aggressive bullish move has propelled the stock well above its 51-day SMA of 1,325.02, supported by a massive spike in trading volume reaching 12.79M.
The RSI (14) has climbed to 71.78, crossing above its signal line (62.85) and entering overbought territory, signaling intense upward momentum and strong buyer conviction in the current trend.
Source: TradingView
Summary
Wockhardt (NSE:WOCKPHARMA) reported a return to profitability in FY26 with improved revenue and EBITDA growth. Q4 performance showed strong gains driven by biotech and emerging markets. Annual results reflected recovery from losses seen in the previous year.
While growth was supported by product developments and regional expansion, regulatory risks and global market dependence remain important factors for future performance
FAQs
- What were Wockhardt’s key financial results for FY26
Wockhardt reported ₹3,373 Cr revenue, ₹630 Cr EBITDA, and ₹238 Cr PBT, marking a turnaround from losses last year - What drove Q4 FY26 performance growth
Growth was driven by higher biotech revenue, strong emerging market demand, and improved operating efficiency - What are the major risks for Wockhardt going forward
Regulatory delays, global demand fluctuations, restructuring costs, and currency volatility may impact future performance